Full Press Release Details
Reaches Milestone in Servier Collaboration
NEW YORK--(BUSINESS WIRE)--July 8, 2015--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS - Nasdaq Global
Market: CLLS), the gene-editing company employing proprietary
technologies to develop best-in-class CAR T-cell products in adoptive
immunotherapy for cancer, today announced the achievement of a
significant milestone under the Company's collaboration agreement with
Servier, in the preclinical development of two next-generation product
candidates in solid tumors.
Under the terms of the Company's collaboration agreement with Servier,
Cellectis is eligible to an undisclosed payment.
The collaboration announced in February 2014, is focused on research,
development, and potentially commercialization of five product
candidates targeting leukemia and solid tumors.
"We are very pleased with the productivity of this alliance enabling us
to accelerate our development in the field of solid tumors," commented
Mathieu Simon, MD, EVP Chief Operating Officer of Cellectis.
"We believe that immunotherapy will dramatically change the management
of metastatic cancers. Our goal at Servier is to make these new
technologies available for the largest number of cancer patients,"
commented Jean-Pierre Abastado, MD, Director Oncology Innovation
Therapeutic Pole of Servier.
Servier is an independent French research-based pharmaceutical company.
Its development is driven by the pursuit of innovation in the
therapeutic areas of cardiovascular, metabolic, central nervous system,
psychiatric, rheumatologic diseases, as well as cancer.
In 2014, the company recorded a turnover of 4 billion euros.
92% of Servier medicines are prescribed outside of France.
28% of turnover from Servier drugs was reinvested in Research and
Development in 2014.
With a strong international presence in 146 countries, Servier employs
more than 21 400 people worldwide.
More information is available at: www.servier.com
Cellectis is a preclinical stage biopharmaceutical company focused on
developing immunotherapies based on gene edited engineered CAR-T cells
(UCART). The company's mission is to develop a new generation of cancer
therapies based on engineered T-cells. Cellectis capitalizes on its 15
years of expertise in genome engineering - based on its flagship TALEN
products and meganucleases and pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets. Cellectis S.A. is
listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
TALEN is a registered trademark owned by the Cellectis Group.
Servier Communication Department
further information:
Director of Communications
Simon Harnest, 646-385-9008
VP Finance and Investor